A Phase 1, Within Cohort, Randomized, Double Blind, Third-party Open, Placebo-controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06826647 In Healthy Subjects And Subjects With Plaque Psoriasis
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Dec 2018
At a glance
- Drugs PF 06826647 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 07 Dec 2018 Planned End Date changed from 3 Jan 2019 to 24 Jan 2019.
- 07 Dec 2018 Planned primary completion date changed from 3 Jan 2019 to 24 Jan 2019.
- 07 Dec 2018 Status changed from recruiting to active, no longer recruiting.